PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
Comparison of Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block With Lateral Femoral Cutaneous Nerve Block (LFCB) Versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB) in Pediatric Hip Surgery: A Randomized Controlled Trial
Poznan University of Medical Sciences
60 participants
Jun 16, 2025
INTERVENTIONAL
Conditions
Summary
This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.
Eligibility
Inclusion Criteria4
- Pediatric patients aged between 2 and 16 years.
- Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries
- ASA (American Society of Anesthesiologists) physical status classification: I-III.
- Written informed consent obtained from the patient's legal guardian(s).
Exclusion Criteria7
- Known allergy or hypersensitivity to any of the study medications
- Presence of infection or inflammation at the intended injection site(s) of regional anesthesia.
- Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks.
- Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs.
- Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation.
- History of chronic opioid use or known substance abuse.
- Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
U-S guided PENG (0.4 mL/kg) with 0.2% ropivacaine
LFCB (0.1 mL/kg) with 0.2% ropivacaine
Lumbar ESPB (0.25ml/kg) with 0.2% ropivacaine
Sacral ESPB (0.25ml/kg) with 0.2% ropivacaine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07023094